Earnings Call · Q4 FY2023·2024-03-13

Q4 23EPS -100.00%*·Rev n/aQ3 23EPS -28.57%·Rev n/aQ2 23EPS +100.00%*·Rev n/aQ1 23EPS -12.50%·Rev n/a⚠ consensus missing

Anika Therapeutics, Inc. ANIK

Mark Namaroff — Chief Executive Officer

Cheryl Blanchard — Chief Financial Officer

Mike Levitz — Chief Commercial Officer

−1.5%1d on move date−1.4% vs SPY3d−1.4%5d−1.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIK calls or request research access.

More ANIK calls Browse calls Request research access